NCI-H2052Homo sapiens (Human)Cancer cell line
Also known as: NCIH2052, H2052_MM, H-2052, H2052
Quick Overview
Human malignant mesothelioma cell line with known genetic alterations.
Detailed Summary
Research Applications
Key Characteristics
Basic Information
| Database ID | CVCL_1518 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Pleural effusion[UBERON:UBERON_0000175] |
Donor Information
| Age | 65 |
|---|---|
| Age Category | Adult |
| Sex | Male |
| Race | caucasian |
Disease Information
| Disease | Pleural mesothelioma |
|---|---|
| Lineage | Pleura |
| Subtype | Pleural Mesothelioma, Sarcomatoid Type |
| OncoTree Code | PLSMESO |
DepMap Information
| Source Type | ATCC |
|---|---|
| Source ID | ACH-000153_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| MutationNone reported | TP53 | - | - | - | PubMed=19787792 |
| MutationSimple | TERT | c.1-124C>T (c.228C>T) (C228T) | Unspecified | In promoter | from parent cell line Hep-G2 |
| MutationSimple | RASSF2 | p.Glu294Ter (c.880G>T) | Heterozygous | - | Unknown, PubMed=25902174 |
| MutationSimple | NF2 | p.Arg341Ter (c.1021C>T) | Homozygous | - | Unknown, Unknown, PubMed=25902174, PubMed=16630136 |
| Gene deletion | LATS2 | - | Homozygous | - | PubMed=21245096 |
| Gene deletion | CDKN2A | - | Homozygous | Possible | PubMed=26870271 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
Pan-cancer proteomic map of 949 human cell lines.";
Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Cancer Cell 40:835-849.e8(2022).
Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
Sellers W.R., Gygi S.P.
Cell 180:387-402.e16(2020).
From clinical specimens to human cancer preclinical models -- a journey the NCI-cell line database-25 years later.
Aldige C.R., Wistuba I.I., Minna J.D.
J. Cell. Biochem. 121:3986-3999(2020).
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
Chemistry-first approach for nomination of personalized treatment in lung cancer.
Posner B.A., Minna J.D., Kim H.S., White M.A.
Cell 173:864-878.e29(2018).
E-cadherin expression is correlated with focal adhesion kinase inhibitor resistance in merlin-negative malignant mesothelioma cells.
Kato T., Sato T., Yokoi K., Sekido Y.
Oncogene 36:5522-5531(2017).
Characterization of human cancer cell lines by reverse-phase protein arrays.
Liang H.
Cancer Cell 31:225-239(2017).
A landscape of pharmacogenomic interactions in cancer.";
Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
Cell 166:740-754(2016).
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Loewer M., Sahin U., Castle J.C.
Genome Med. 7:118.1-118.7(2015).
Functional differences between wild-type and mutant-type BRCA1-associated protein 1 tumor suppressor against malignant mesothelioma cells.
Yokoi K., Sekido Y.
Cancer Sci. 106:990-999(2015).
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Golub T.R., Root D.E., Hahn W.C.
Sci. Data 1:140035-140035(2014).
Hippo pathway gene mutations in malignant mesothelioma: revealed by RNA and targeted exon sequencing.
Asamura H., Gemma A., Yamada T.
J. Thorac. Oncol. 10:844-851(2015).
A resource for cell line authentication, annotation and quality control.
Neve R.M.
Nature 520:307-311(2015).
A comprehensive transcriptional portrait of human cancer cell lines.
Settleman J., Seshagiri S., Zhang Z.-M.
Nat. Biotechnol. 33:306-312(2015).
Frequent coamplification and cooperation between C-MYC and PVT1 oncogenes promote malignant pleural mesothelioma.
Rice D.C., Tsao A., Wistuba I.I.
J. Thorac. Oncol. 9:998-1007(2014).
Integrated high-resolution array CGH and SKY analysis of homozygous deletions and other genomic alterations present in malignant mesothelioma cell lines.
Meltzer P.S., Kirsch I.R., Kaye F.J., Roschke A.V.
Cancer Genet. 206:191-205(2013).
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
Nature 483:603-607(2012).
The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma.
Powell S.N., Zhou Q., Shen R.-L., Olshen A.B., Rusch V.W., Ladanyi M.
Nat. Genet. 43:668-672(2011).
LATS2 is a tumor suppressor gene of malignant mesothelioma.";
Sekido Y.
Cancer Res. 71:873-883(2011).
MicroRNA expression distinguishes SCLC from NSCLC lung tumor cells and suggests a possible pathological relationship between SCLCs and NSCLCs.
Gazdar A.F., Pertsemlidis A.
J. Exp. Clin. Cancer Res. 29:75.1-75.12(2010).
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Haber D.A.
Cancer Res. 70:2158-2164(2010).
Signatures of mutation and selection in the cancer genome.";
Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Nature 463:893-898(2010).
Combined treatment with cisplatin and sirolimus to enhance cell death in human mesothelioma.
Hartman M.-L., Esposito J.M., Yeap B.Y., Sugarbaker D.J.
J. Thorac. Cardiovasc. Surg. 139:1233-1240(2010).
Genomic profiling of malignant pleural mesothelioma with array-based comparative genomic hybridization shows frequent non-random chromosomal alteration regions including JUN amplification on 1p32.
Sekido Y.
Cancer Sci. 98:438-446(2007).
Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients.
Yokoi K., Horio Y., Shimokata K., Sekido Y., Hida T.
Cancer Sci. 97:387-394(2006).
Searching for microsatellite mutations in coding regions in lung, breast, ovarian and colorectal cancers.
Minna J.D.
Oncogene 20:1005-1009(2001).
Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer.
Modi S., Kubo A., Oie H.K., Coxon A.B., Rehmatulla A., Kaye F.J.
Oncogene 19:4632-4639(2000).
Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering.
Girard L., Zochbauer-Muller S., Virmani A.K., Gazdar A.F., Minna J.D.
Cancer Res. 60:4894-4906(2000).